Targets › SELENOW
2 programs from 2 companies in 2 trials: 1 Phase 3, 1 Phase 2; Cardiovascular, Psychiatry; next expected readout Apr 2027.
Plays a role as a glutathione (GSH)-dependent antioxidant. May be involved in a redox-related process. (UniProt, P63302)
Open in Phaseline: the race on SELENOW, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Skane University Hospital | Selenium (Bio-SelenoPrecise) Selenium supplementation; trace element cofactor for selenoproteins involved in antioxidan | SELENOP, SELENOW | Phase 3 | Heart Failure | Mar 2030 |
| First Affiliated Hospital of Chongqing Medical University | selenium yeast supplementation selenium cofactor for selenoprotein synthesis | SELENOP, SELENOK, SELENOW, SELENOF | Phase 2 | Depression - Major Depressive Disorder | Apr 2027 |
Heart Failure (1) Depression - Major Depressive Disorder (1)
small molecule (1)
Skane University Hospital (1) First Affiliated Hospital of Chongqing Medical University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.